Quick Facts

EU-OPENSCREEN integrates high-capacity screening platforms throughout Europe, which jointly use a rationally selected compound collection, comprising up to 140.000 commercial and proprietary compounds collected from European chemists.

EU-OPENSCREEN will collaboratively develop novel molecular tool compounds with external users from various disciplines of the life sciences. EU-OPENSCREEN has no bias towards target families, biological topics or models. EU-OPENSCREEN explicitly advocates wide-ranging projects that will enhance cross-fertilization between disciplines.

EU-OPENSCREEN supports all stages of a tool development project, including assay adaptation, high-throughput screening, and chemical optimisation of the ‘hit’ compounds. All generated tool compounds and data will be made available in an open access database.

EU-OPENSCREEN builds on chemical biology networks and their facilities in 13 European partner countries (Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Latvia, Netherlands, Norway, Poland, Spain, Sweden and Romania) and 1 international organization (EMBL). The EU-OPENSCREEN Central Office is located at the Leibniz-Institut für Molekulare Pharmakologie (FMP) in Berlin. EU-OPENSCREEN will start operating as a permanent ERIC (European Research Infrastructure Consortium) in 2018.